[{"id":"76e96c90-172a-4d33-b0d4-aad64c0013c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01033240","created_at":"2021-04-09T02:52:34.130Z","updated_at":"2024-07-02T16:36:32.188Z","phase":"Phase 2","brief_title":"CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer","source_id_and_acronym":"NCT01033240","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • tigatuzumab (CS-1008)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 07/09/2010","start_date":" 07/09/2010","primary_txt":" Primary completion: 07/13/2012","primary_completion_date":" 07/13/2012","study_txt":" Completion: 09/09/2013","study_completion_date":" 09/09/2013","last_update_posted":"2021-04-08"},{"id":"1c573dd4-69f2-409c-b09f-5cc0b5a15d20","acronym":"","url":"https://clinicaltrials.gov/study/NCT01307891","created_at":"2021-01-18T05:19:25.464Z","updated_at":"2024-07-02T16:37:16.840Z","phase":"Phase 2","brief_title":"Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer","source_id_and_acronym":"NCT01307891","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • tigatuzumab (CS-1008)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2017-10-26"}]